ORYZON receives European Medicines Agency approval to initiate the HOPE-2 Phase II study ... 29/09/2026 Healthcare Rare diseases Innovative drugs PMS is a severely disabling genetic disorder related to autism. Partners - Oryzon Genomics
CONNECTA Therapeutics Announces Financing to Advance Clinical Development of Fragile X Sy... 10/09/2026 Healthcare Rare diseases Innovative drugs €3.1 million financing led by new investor Clave Capital, with participation from existing investors. Partners - CONNECTA THERAPEUTICS
Atlas Molecular Pharma to Begin Dosing First Patients in Phase 2 Trial of ATL-001 for Cong... 03/09/2026 Healthcare Rare diseases Innovative drugs Atlas Molecular Pharma, a Basque biotech developing pharmacological chaperone therapies for rare diseases, announces... Partners - Atlas Molecular Pharma
Almirall and Certest Biotec enter strategic research collaboration and licensing agreement 31/08/2026 Healthcare Rare diseases Innovative drugs Almirall and Certest Biotec, S.L., through its pharmaceutical division, Certest Pharma, have entered into a strategic... Partners - CERTEST BIOTEC
An Opportunity to Transform Research on Rare Diseases in Europe 24/07/2026 Healthcare Rare diseases Personalized medicine Between 27 and 36 million people in the European Union live with one of the 6,000 to 8,000 known rare diseases. Partners - GENESIS Biomed
ORYZON announces U.S. patent grant for vafidemstat in borderline personality disorder (BP... 08/07/2026 Healthcare Rare diseases Innovative drugs Granted claims cover the use of vafidemstat for treating non-aggressive symptoms of BPD. Partners - Oryzon Genomics
World ALS Day | “ALS research is currently going through a particularly promising moment” 21/06/2026 Healthcare Rare diseases Innovative drugs Personalized medicine We interview Alfonso de Egaña Barrenechea, CEO of Molefy Pharma, a company developing AP-2, an innovative molecule... AseBio - MOLEFY PHARMA
Research on the TDP-43 protein opens new therapeutic avenues for ALS 20/06/2026 Biotechnology is driving new strategies to combat ALS, including research on the TDP-43 protein, a key target involved... AseBio
Shilpa Biocare Invests in Gate2Brain to Advance G2B-002, an Innovative Brain Cancer Thera... 16/06/2026 Healthcare Rare diseases Innovative drugs Gate2Brain signs a strategic partnership with Shilpa Biocare, including a €7 million investment for a 30.4% equity stake... Partners - Gate2Brain
Miramoon Pharma Wins Second Prize at ARVO 2026 Eye Pitch Competition 27/05/2026 Healthcare Rare diseases Advanced therapies The startup receives $15,000 award for its innovative MP-004 therapy targeting retinitis pigmentosa. Partners - Miramoon Pharma
